SCHEMBL3326355

SCHEMBL3326355

c1cc(-c2cc3cnccc3c(NCC3CCNCC3)n2)ccn1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKCD Q05655 12/20 0.58
PRKCH P24723 11/20 0.58
PRKCE Q02156 11/20 0.58
PRKCA P17252 10/20 0.58
PRKCQ Q04759 9/20 0.58
PRKCB P05771 6/20 0.58
PRKD1 Q15139 4/20 0.58
ROCK2 O75116 2/20 0.58
ROCK1 Q13464 2/20 0.58
PKN1 Q16512 2/20 0.58
PKN2 Q16513 2/20 0.58
CYP1A2 P05177 1/20 0.55
LATS1 O95835 2/20 0.51
LATS2 Q9NRM7 1/20 0.51
TRIM58 Q8NG06 2/20 0.45
SYK P43405 2/20 0.43
KCNH2 Q12809 2/20 0.43
AURKB Q96GD4 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3327386 0.82 PRKCD (0.56) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3325544 0.81 PRKCD (0.55) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3325550 0.81 PRKCD (0.55) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3324491 0.75 GPR119 (0.54) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3327404 0.74 PRKCD (0.54) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3327772 0.74 PRKCD (0.54) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3327608 0.74 PRKCH (1.00) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3327421 0.74 PRKCZ (0.59) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL25142443 0.73 PRKCD (0.62) PRKCDPRKCHPRKCEPRKCAPRKCQ
SCHEMBL3327285 0.73 PRKCH (1.00) PRKCDPRKCHPRKCEPRKCAPRKCQ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130469-A1 2, 6-NAPHTHRIDINE DERIVATIVES VAN EIS MAURICE 2010-05-27 US disclosed
US-20100130469-A1 2, 6-NAPHTHRIDINE DERIVATIVES VAN EIS MAURICE 2010-05-27 US disclosed
US-20100130469-A1 2, 6-NAPHTHRIDINE DERIVATIVES VAN EIS MAURICE 2010-05-27 US disclosed
EP-2144908-A1 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS Novartis Ag (CH) 2010-01-20 EP disclosed
WO-2008122614-A1 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2008-10-16 WO disclosed
WO-2008122614-A1 2, 6-NAPHTHYRIDINE DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130469-A1 2, 6-NAPHTHRIDINE DERIVATIVES PKN1, PKN2, CDK9 PRKCD 63/4885PRKCH 22/4885PRKCE 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.